Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Liabilities and Shareholders Equity (2020 - 2024)

Immuneering has reported Liabilities and Shareholders Equity over the past 5 years, most recently at $68.6 million for Q3 2024.

  • Quarterly results put Liabilities and Shareholders Equity at $68.6 million for Q3 2024, down 39.8% from a year ago — trailing twelve months through Dec 2024 was $233.6 million (down 47.97% YoY), and the annual figure for FY2023 was $102.6 million, down 16.17%.
  • Liabilities and Shareholders Equity for Q3 2024 was $68.6 million at Immuneering, down from $77.1 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for IMRX hit a ceiling of $166.7 million in Q4 2021 and a floor of $38.4 million in Q4 2020.
  • Median Liabilities and Shareholders Equity over the past 5 years was $113.9 million (2023), compared with a mean of $110.4 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: soared 333.87% in 2021 and later tumbled 39.8% in 2024.
  • Immuneering's Liabilities and Shareholders Equity stood at $38.4 million in 2020, then soared by 333.87% to $166.7 million in 2021, then dropped by 26.6% to $122.4 million in 2022, then dropped by 16.17% to $102.6 million in 2023, then plummeted by 33.17% to $68.6 million in 2024.
  • The last three reported values for Liabilities and Shareholders Equity were $68.6 million (Q3 2024), $77.1 million (Q2 2024), and $88.0 million (Q1 2024) per Business Quant data.